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INTRODUCTION
Thyroid carcinoma is the most common endocrine malignancy. [1] Of all malignant cases in the thyroid, >90% are well-differentiated thyroid carcinomas (papillary thyroid carcinoma 80%, follicular thyroid carcinoma 10-15%). [1, 2] The diagnosis of benign and malignant thyroid lesions is easily made by cytomorphological and histomorphological evaluation on H and E stained slides. Diagnostic difficulties may occur in encapsulated follicular lesions with a suspicious capsule and vascular invasion and with an absence of the characteristic nuclear features of papillary carcinoma. This can lead to serious differences among pathologists in the evaluation of the same lesion. [1, 2] In morphologically overlapping cases, immunohistochemistry is necessary for the differential diagnosis. Although the most commonly used immunohistochemical (IHC) markers are Hector Battifora Mesothelial 1 (HBME-1), galectin-3 and Cytokeratin 19 (CK19), none of these markers provide 100% differential diagnosis because of expression in both neoplastic and non-neoplastic lesions. [1] [2] [3] TROP-2, also referred to as GA733-1 (gastric antigen 733-1), MIS-1 (surface marker 1, EGP-1 (epithelial glycoprotein-1), is a transmembrane receptor glycoprotein encoded by the tumor-associated calcium signal transducer 2 (Tacstd2) gene, which is located on chromosome 1p32. [4] TROP-2 was first discovered on the surface of trophoblast cells. [5] TROP-2 over-expression is associated with diverse clinicopathological factors and poor clinical outcome in various types of epithelial cancers including breast, gastric, colorectal, endometrial and ovarian cancers. [5] [6] [7] [8] [9] [10] There are few studies in literature which have investigated TROP-2 expression in thyroid neoplasms. In some of these, the immunoreactivity of this new marker has been studied on microarrays and cytological samples. In addition, the sensitivity and specificity of TROP-2 expression have been reported to be high in papillary thyroid carcinomas. [11] [12] [13] [14] [15] The aim of this study was to evaluate the expression of TROP-2 and, using IHC, to analyse its sensitivity in the differentiation of benign and malignant thyroid lesions.
SUBJECTS AND METHODS

Case selection
This retrospective study was conducted on 152 cases of thyroid neoplasm that were histopathologically diagnosed using thyroidectomy tissue at Antalya 
Immunohistochemistry staining
All cases were reviewed by 2 pathologists to establish the histological type and characteristics of the tumours according to World Health Organization criteria (2004). All samples were routinely fixed for 24 hours in 10% buffered formaldehyde, then embedded in paraffin blocks and sections were cut of 4 μm thickness onto positively charged slides for immunohistochemical application. The tissue sections were deparaffinised in xylene and rehydrated using graded alcohol and deionised H 2 O. For antigen retrieval, the tissue sections were immersed in a 10% citrate buffer solution (#RE7113; Leica Microsystems, Inc., Milton Keynes, UK) and heated in the microwave at 800 W for 15 min. Endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide for 10 min. Slides were incubated with mouse monoclonal TROP-2 (dilution, 1:400; cat. no. (B-9): sc-376746; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies for 60 min at room temperature. After washing with phosphate buffered saline (PBS), the slides were incubated with biotinylated secondary antibodies (#BP-9100; undiluted; Vector Laboratories, Burlingame, CA, USA) for 20 min at 30˚C, then washed with PBS for 5 min and incubated with the Peroxidase Detection system Ready to Use conjugated antibody (#RE7110K; Novocastra; Leica Microsystems, Inc.) for 20 min at room temperature. Subsequently, the sections were washed with PBS for 5 min, incubated with chromogenic 3,3'-diaminobenzidine (Leica Microsystems, Inc.) for 5 min, washed with tap water and counterstained with hematoxylin. The slides were then dehydrated in ascending grades of alcohol and stained with xylene.
Evaluation of immunohistochemical staining
Membranous staining of squamous cells of the normal skin was used as positive control. In all thyroid cases, membranous staining of the cells was accepted as positive. The proportion of positively stained cells was scored as follows; 0: negative or <5% positively stained cells, 1:6%-25% positively stained cells, 2:25%-50% positively stained cells, 3: 51%-74% positively stained cells, 4:>75% positively stained cells. [13] In the positive cases, 1+ or 2+ were accepted as focal staining pattern and diffuse staining pattern (3+ or 4+). [13] Statistical analysis The statistical analysis was performed using SPSS version 17 software (SPSS Inc., Chicago, U.S.A.). The Pearson Chi-square test or Fisher Exact test were used to assess the differences between groups. The sensitivity of TROP-2 was compared between the benign and malignant groups. A value of P < 0.05 was accepted as statistically significant.
RESULTS
The study cases comprised 79% (120/152) females and 21% (32/152) males with a median age of 46.8 years (range, 15-85 years). The TROP-2 expression values in the 152 thyroid lesions are shown in Table 1 . TROP-2 expression was positive in 74.6% (56/75) of the malignant thyroid lesions and in 1.3% of benign thyroid lesions. There was a statistically significant difference (P < 0.001) between the benign and malignant lesions. Immunoreactivity was detected in only 1 of the 29 patients with FA. Hashimoto's thyroiditis was present as an additional thyroid pathological finding in 23 cases. In 5 cases of Hashimoto's thyroiditis, membranous staining was determined in oncocytic cells in and outside lymphoid aggregates [ Figure 1 ]. TROP-2 expression was seen in 89.5% (51/57) of PTC and in 41.7% (5/12) of FC, while all MTC, PDTC and UDTC were not stained. When the PTC cases were compared according to the staining percentage of tumor cells in the follicular carcinoma cases, most of the cases showed a diffuse staining pattern [ Figure 2 ].
The TROP-2 expression distribution in the PTC cases in this study is shown in Table 2 . All mPTC, 89.4% (17/19) of PTC cv, 81.8% (9/11) of PTC fv, and 66.6% (4/6) of PTC ov showed expression [ Figure 3 ]. The percentage of staining of PTC fv showed more focal staining compared to other PTC. TROP-2 expression was also shown to differentiate the various follicular lesions of the thyroid [ Table 3 ]. Immunoreactivity was detected in 3.4% (1/29) of FA, in 41.7% (5/12) of FC and in 81.8% (9/11) of PTC fv cases. The difference was found to be statistically significant between PTC fv and FA (P < 0.01), and between FA and FTC (P = 0.05). The difference between FTC and PTC fv was not statistically significant (P = 0.089).
A review of literature and the data of the current study are presented in Table 4 .
DISCUSSION
Thyroid carcinoma is the most common endocrine malignancy. [1] The distinction between benign and malignant lesions is very important because there are significant differences in prognostic and metastatic characteristics. [1, 16] Many studies have investigated immunohistochemistry as a complementary method in the diagnosis of thyroid tumours when the morphology is inadequate. [17] [18] [19] [20] Immunohistochemical markers such as HBME-1, Galectin 3, CK19, CİTED-1, CD44, CD56 have been found to be useful in distinguishing benign from malignant lesions. [16] [17] [18] [19] [20] However, immunoreactivity in benign follicular disease and in follicular adenoma restricts the use of the markers. [21, 22] Hürtle (oncocytic) cell is characterized by the cytoplasmatic accumulation of mitochondria, on electron microscope and has rich endogenous biotin. This cell can be seen in benign and malignant thyroid diseases, including Hashimoto's thyroiditis, oncocytic adenoma, oncocytic carcinoma or oncocytic variant of papillary thyroid carcinoma. [16, 23, 24] It may often display cytological atypia and abnormal staining with immunohistochemical markers. Cells may provide false positive results, especially when heat-induced antigen retrieval methods are used. [21] TROP-2 expression in benign thyroid lesions has been reported in only one study. However, Addati et al. indicated immunoreactivity in 2 FA and 4 non-neoplastic thyroid tissue samples. [11] In the current study, 4 of the 29 follicular adenomas had an oncocytic variant and only 1 was stained. However, Hashimoto's thyroiditis was detected as an additional pathological finding in 23 of the 152 cases and 5 of those showed membranous staining in oncocytic cells in and outside lymphoid aggregates.
In the current study, a statistically significant difference was determined between benign and malignant lesions and TROP-2 expression was most frequently observed in well-differentiated thyroid cancers of the malignant thyroid lesions. All MTC, PDTC and UDTC were negative for TROP-2. No report in literature has shown TROP-2 staining for MTC, whereas 2 PDTC and 1 UDTC were positive only in papillary areas in the study by Bychkov et al. [14] In the current study, TROP-2 expression tended to be focal staining in the FC cases compared to the PTC cases. In addition, TROP-2 expression was higher in the current study cases compared with previous findings in the literature. Bychkov et al. reported no positivity in 35 FTC cases in a study of fixed paraffin-embedded (FFPE) samples while two TMA-based studies showed positivity in 1 of 64 cases. [12] [13] [14] This difference may have been caused by the use of different clones or TMA samples.
In previous studies, the sensitivity of TROP-2 expression for PTC has been calculated to be between 50% and 90%. [11] [12] [13] [14] [15] In the current study, 89.5% sensitivity was determined for PTC. Moreover, sensitivity was 100% and 89.4% for mPTC and PTCcv cases, respectively, in accordance with the literature. [12] [13] [14] [15] In the present study, the sensitivity rate of PTC fv was high compared to the three studies in the literature which used the same antibody. [12] [13] [14] However, the study results of Adati et al. using different antibody from these studies was similar to the current study findings. [11] When TROP-2 expression was examined in terms of differentiation between benign and malignant follicular lesions, a statistically significant difference was determined between PTC fv and FA (P < 0.01), and between FA and FTC (P = 0.05), but no difference was found between FTC/PTC fv (P = 0.089).
CONCLUSION
The results of this study demonstrated that TROP-2 has high specificity for the diagnosis of thyroid papillary carcinoma and especially for some subtypes (PTC cv, PTC fv and mPTC). TROP-2 can be considered a promising new marker that helps to differentiate between benign and malignant follicular lesions.
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